Important safety information on Strattera® (atomoxetine) and increased blood pressure and heart rate

Eli Lilly (S) Pte Ltd would like to update healthcare professionals on safety information from clinical studies regarding risk of increased blood pressure and increased heart rate with the use of atomoxetine. A recent analysis of combined data from Eli Lilly sponsored trials has indicated that a proportion of atomoxetine-treated patients (approximately 5 to 10% of children and adults) experienced clinically important changes in heart rate (20 beats per minute or greater) or blood pressure (15 to 20 mm Hg or greater). The magnitude of the increase in blood pressure and heart rate could be a potential risk in patients with severe cardiovascular disorders. Although the current prescribing information for Strattera® already contains warnings that atomoxetine may increase blood pressure and heart rate, it will be further strengthened to highlight the above safety information.